Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

At close: 7 February at 15:00:00 GMT-5 ...

At close: 5:30:23 PM GMT+1 ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

All relevant comments and Antipa Minerals Ltd share chat regarding the AZY ASX share news are listed here in the AZY forum. View and contribute to the AZY share chat. Discuss Antipa Minerals Ltd share ...

RM has received institutional research grants or consulting fees from Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, CPC Clinical Research, Cordis, Elixir Medical, ...

The sponsors had no role in the design or conduct of this study. Competing interests MJH received consultancy honoraria from Actelion, Idorsia and Pfizer. The remaining authors declare no conflicts of ...